Improving Access to Test and Counselling Services for Injection Drug Users: Most Recent Experience from Portugal. Henrique Barros

Similar documents
Hepatitis prevention in the context of HIV prevention point work in Latvia

Poland nationalupdate

Prevalence of HIV and risk behaviors among injecting drug users in Tallinn, Estonia in a series of cross-sectional studies

Civil Society Driven Response in Ukraine: A program making a difference and bringing results

STATISTICAL BULLETIN 2016

HIV AND PEOPLE WHO INJECT DRUGS

Strategies of drug users to avoid infection with hepatitis C

The new German strategy on HIV, Hepatitis B, C and STI, an integrated approach. Ines Perea Ministry of Health, Germany

NATIONAL PRIORITIES FOR HIV/AIDS IN THE WORLD OF WORK

STATISTICAL BULLETIN 2015

Harm reduction among drug users in Spain

HIV/AIDS Epidemic Status at-a-glance

Models of good practice in drug treatment in Europe. Project group

Additional North Carolina Projects

HARM REDUCTION IN ASIA. Adeeba Kamarulzaman University of Malaya, Kuala Lumpur

INTRAVENOUS INJECTING DRUG USE.

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

Performance Management Plan Indicator Worksheet #1

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

The evolution of the HIV/AIDS outbreak among IDUs in Romania

Chiang Mai University/Johns Hopkins University HIV/AIDS Research on VCT

UNGASS Declaration of Commitment on HIV/AIDS: Core Indicators revision

The impact of economic recession on drug users and drug treatment

The Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC

Government of Canada Federal AIDS Initiative Milestones

Drug Policy and the HIV Movement. SAULIUS CAPLINSKAS MD, PhD

ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)

Drug Consumption Rooms Worldwide

U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

National HIV Behavioral Surveillance Portland, Oregon

ELPA S VISION OF SCREENING

NEEDLE AND SYRINGE PROGRAMMES MONITORING IN LITHUANIA

Harm Reduction in Nigeria

TB: INTEGRATION IN HARM REDUCTION PACKAGES. ICF "AIDS Foundation East-West (AFEW Ukraine) Tbilisi, 2015

Harms and harm reduction workbook. Country X

Public drug policies Catalonia

Testing, Prevention and Care IDU in Chicago, 2009

Summary Report: Survey of Hepatitis C Virus counseling and testing services at HIV counseling and testing sites, and health service sites.

OST saves lives it s official! OST a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success

From Fix to Foil. The Dutch experience in promoting transition away from injecting drug use,

HIV treatment cascade and epidemiological analysis of the new HIV outbreak in injecting drug users from Luxembourg

HIV EPIDEMIC UPDATE: FACTS & FIGURES 2012

The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015

STI and HIV Prevention and Care among Sex Workers

HIV in Prison Situation in Frankfurt am Main

Minutes of the 18 th HIV/AIDS Think Tank Meeting 5 and 6 June 2012, Luxembourg

UNGASS COUNTRY PROGRESS REPORT SINGAPORE

Integrated harm reduction services for drug users and homeless people. Katrin Schiffer

Experiences of site visits to Estonian low threshold service centres - improving TB case-finding and infection control

Hepatitis and HIV Co-Infection: Situation in Ukraine.

Drug Use, Harm Reduction, and HIP

UNAIDS 99.1E (English original, March 1999) This document, presenting a speech given at the United Nations General Assembly Special Session on Drugs,

EMCDDA-update HIV/HCV among people who inject drugs: situation and response

PREVENTION STRATEGIES RELATED TO HIV/AIDS Narra Smith Cox, Ph.D., CHES

Viral Hepatitis. WHO Regional Office for Europe July 2013

HIV epidemic around the Baltic Sea

ECDC and Spanish Ministry of Health workshop:

DHMH Activities toward Implementing Requirements of Md. Code Ann., Health-General , Hepatitis C Prevention and Control within Maryland

Review on HIV & Associated Infections in Latvia

UNGASS COUNTRY PROGRESS REPORT Republic of Armenia

HIV/AIDS MODULE. Rationale

Part of the Continuum of Care. Harm Reduction. Gino Vumbaca President Harm Reduction Australia

Hepatitis C Strategy. About us. What is hepatitis C?

Rolling up HCV treatment programs for PWIDs in Ukraine

Most recent data, analyses and feed-back from the 2016 DRID national updates

Thirty years of harm reduction in the Netherlands HCV elimination ahead?

Groups of young people in Uganda that need to be targeted with HIV interventions

Blood-borne viruses in marginalised populations

Prevention and care towards vulnerable and stigmatized populations (MSM, drug users, sex workers)

ENDING THE EPIDEMICS: A NATIONAL, STATE, AND CITY APPROACH

Hepatitis C Virus Infection Among Young Drug Users What Can Viral Hepatitis Coordinators and Health Departments Do?

PERFORMANCE AND IMAGE ENHANCING DRUGS

Republic of Bulgaria. Reporting period: January 2003 December National Committee on Prevention of AIDS and STDs at the Council of Ministers

Feedback from joint country mission on HIV and hepatitis B and C of ECDC and EMCDDA experts to Latvia, September 2014

Promoting hepatitis B vaccination

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy

THE REPUBLIC OF BELARUS

World Health Organization. A Sustainable Health Sector

Formative Research results

Young People and HIV/AIDS

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

Glossary of Acronyms. AIDS - Acquired Immunodeficiency Syndrome. CDC - Centers for Disease Control and Prevention. DHS - Department of Health Services

Transport against HIV/AIDS Monitoring and Evaluation Framework report

Technical Guidance Note for Global Fund HIV Proposals

As a result of this training, participants will be able to:

Note: Staff who work in case management programs should attend the AIDS Institute training, "Addressing Prevention in HIV Case Management.

China Country Advocacy Brief Injecting Drug Use and HIV

HIV/AIDS Think Tank meeting: EMCDDA report. Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015

Comprehensive HIV/AIDS Resources and Linkages for Inmates (CHARLI) and Care Coordination (CC) Collaborative. Care Coordination

Hepatitis C Elimination Program Georgia

Statement by the Portuguese Deputy Minister for Health. Vienna, 8 March 2010

Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention

Ontario Harm Reduction Conference April 30 to May 2, 2017 Toronto, Ontario

High Impact Prevention for People Who Inject Drugs. June 30, 2015

ANNUAL REPORT ON THE DRUG PHENOMENA. Commissioned by the European Monitoring Centre on Drugs and Drug Addiction IPDT 1

Related Problems in Portugal

Project Connections Buprenorphine Program

What is harm reduction?

COUNTRY TABLE. MONTENEGRO.

Transcription:

Improving Access to Test and Counselling Services for Injection Drug Users: Most Recent Experience from Portugal Henrique Barros Ministério da Saúde

HIV Testing Knowledge of HIV serostatus has been increasingly advocated as a prevention measure in its own right.

Most commonly stated barriers to HIV testing: being aware of a negative test a preference not to know perception of low risk for HIV concerns about losing employment and life assurance.

HIV Testing AIDS programmes need to be able to make comparisons about what works and doesn t work; and to estimate the resources required at country, regional, and global levels to provide universal access to HIV prevention services

HIV Testing Rapid point-of-care HIV testing is a very important component of HIV control initiatives and programs. Non-invasive, simple, accurate (blood or oral fluid-based) rapid tests have the potential to make a big impact on HIV screening programs, especially in areas where laboratory infrastructure is poor or unavailable

HIV Testing

HIV and Drug Users Over the past decade, a body of observational research has accumulated about the effects of outreach-based and peer added HIV interventions for drug users.

HIV and Drug Users Chen et al. AIDS Behav, 26

HIV and Drug Users Drug Users in Portugal 3, clients contact the public health and social services for drug users; Approximately 15, DUs are reached by harm reduction structures.

12 1 8 6 4 2 AIDS Cases - Portugal 1983 84 85 86 87 88 89 199 91 92 93 94 95 96 97 98 99 2 1 2 3 4 5 Date of diagnosis Date of declaration

HIV and Drug Users HIV Notifications 1.5 1.125 75 375 21 22 23 24 25 UDIs HS MSM MTCT

HIV and Drug Users AIDS Notifications 55, 412,5 275, 137,5, 21 22 23 24 25 IDUs HS MSM MTCT

HIV new infections in IDUs (per 1,, population) 14 11 7 36 2.7.9.7 3 2 3 21 1.8.2 3 18 9 28 24 63 3 7 5 43 3 5 98 72 3 12 17.1 12 2 31 1 NA NA 14 11 7 36 2.7.9.7 3 2 3 21 1.8.2 3 18 9 28 24 63 3 7 5 43 3 5 98 72 3 12 17.1 12 2 31 1 NA NA

HIV/AIDS patients on HAART (26), by region 15. 11.25 11.273 7.5 5.134 3.75 1.328 799 145 ARS Norte ARS Centro ARS LVT ARS Alentejo ARS Algarve

Distance from usual residence to hospital

23 24 25 26 n 3 25 2 15 1 5 Modes of Transmission HSJ, 1985-26 199 1991 1992 1993 1994 1995 1996 1997 1998 1999 2 21 22 Tx, Hemof MSM Heterosexual IDUs 1989 1988 1987 1986 1985

HIV and Drug Users Programs for Injection Drug Users: Needle and syringe exchange Substitution therapy Medically assisted injection facilities

HIV and Drug Users Syringe Exchange Kit

HIV and Drug Users syringes 1.8. 1.6. 1.4. 1.2. 1.. 8. 6. 4. 2. Pharmacies Partnerships protocols w ith NGO Mobile Units 23 24 25

HIV and Drug Users - Portugal Modelling of the effect of the Needle Exchange Programme on HIV prevalence among IDUs. NO YES

Survey of two Portuguese Prisons HIV prevalence according to lifetime drug use. Men Women n HIV + n HIV + None 64 1 (1.6%) 223 15 (6.7%) Only cannabis 51 1 (2.%) 72 4 (5.6%) Only heroin 1 (.%) 1 (.%) Only cocaine 3 (.%) 7 (.%) Only other drugs* 1 (.%) 2 (.%) Cannabis+heroin - 1 (.%) Cannabis+cocaine 16 (.%) 27 2 (7.4%) Cannabis+other drugs* 18 (.%) 6 (.%) Cannabis+heroin+cocaine 24 9 (37.5%) 18 5 (27.8%) Cannabis+heroin+other drugs* - - Cannabis+cocaine+other drugs* 19 (.%) 15 (.%) Heroin+cocaine 1 (.%) - Heroin+other drugs* - 1 (.%) Cocaine+ other drugs * 1 (.%) - Heroin+cocaine+ other drugs * - - Cannabis+heroin+cocaine+ other drugs * 51 13 (25.5%) 39 15 (38.5%)

Survey of two Portuguese Prisons Prevalence of infection according to IDU and sharing of injection material in men. n HIV HBV HCV Syphilis Chlamydia n (%) n (%) n (%) n (%) n (%) Overall 271 24 (8.9) 5 (1.9) 59 (21.8) 6 (2.2) 19 (6.) Never used injected drugs 198 2 (1.) 1 (.5) 7 (3.5) 3 (1.5) 19 (8.1) Used injected drugs/never shared injection material 23 6 (26.1) 1 (4.4) 21 (91.3) (.) (.) Used injected drugs/ever shared injection material 32 16 (5.) 1 (3.1) 3 (93.8) 1 (3.1) (.) Prevalence of infection according to IDU and sharing of injection material in women. n HIV HBV HCV Syphilis Chlamydia n (%) n (%) n (%) n (%) n (%) Overall 445 44 (9.9) 9 (2.) 51 (11.5) 16 (3.6) 5 (1.) Never used injected drugs 37 21 (5.7) 6 (1.6) 13 (3.5) 11 (3.) 4 (1.) Used injected drugs/never shared injection material 17 4 (23.5) 1 (5.9) 9 (52.9) 1 (5.9) (.) Used injected drugs/ever shared injection material 28 16 (57.1) 1 (3.6) 22 (78.6) 2 (7.1) 1 (3.2)

Survey of two Portuguese Prisons Men Non IDUs IDUs never sharers IDUs ever sharers n HIV HCV HIV/HCV 198 23 32 2(1.) 6 (26.1) 16 (5.) 7 (3.5) 21 (91.3) 3 (93.8) (.) 6 (26.1) 16 (5.) p <.1 <.1 <.1 Women Non IDUs IDUs never sharers IDUs ever sharers 37 17 28 21 (5.7) 4 (23.5) 16 (57.1) 13 (3.5) 9 (52.9) 22 (78.6) 5 (1.4) 2 (11.7) 14 (5.) p <.1 <.1 <.1

HIV and Drug Users Drug treatment public services [1] Public Detoxification Units 23 % 24 % 23 % 24 % First-time clients 5212 523 Clients 1873 1792 HIV testing 1443 27, 1154 23, HIV testing 1812 96,7 1641 91,6 HIV+ 219 15,2 141 12,2 HIV+ 289 15,9 225 13,7 ARV treatment 62 4,3 27 2,3 ARV treatment 98 5,4 71 4,3 Certified Detoxification Units 23 % 24 % Clients 1493 1579 HIV testing 955 64, 1183 74,9 HIV+ 151 15,8 147 12,4 ARV treatment 8 8,4 63 5,3 [1] IDT. Relatório Anual. 23 A Situação do País e Matérias de Drogas e Toxicodependências. Vol.I Informação Estatística.23. IDT. Relatório Anual. 24 A Situação do País e Matérias de Drogas e Toxicodependências. Vol.I Informação Estatística.24

UD 1st visit (1) Evaluation UD Active (2) screening N&Psy Information + questionnaire Usual Situation (3) Pre-test counselling N&Psy TEST (+) TEST (-) (4) Test N&Psy MEDICAL DOCTOR 5(VIH+) Post-test counselling N&Psy (6) Test confirmation (7+) Post-test counselling N&Psy 5(VIH-) Post-test counselling N&Psy 7(VIH-) Post-test counselling N&Psy (8) Referal Or Social worker Discussion about options (9) Hospitalar (1) Social work services

HIV and Drug Users Portuguese Programme

HIV and Drug Users Portuguese Programme

HIV and Drug Users Portuguese Programme

HIV and Drug Users Portuguese Programme

HIV and Drug Users Portuguese Programme

HIV and Drug Users Portuguese Programme

HIV and Drug Users Portuguese Programme Norte 13 CAT 1 2 8 1+2 1 2 1 1+1 Centro 11 CAT 3+2 2 2 9+6 2 2 LVT 15 CAT 4+3 1+1 Alentejo 4 CAT 1+1 2+2 Algarve 2 CAT

HIV and Drug Users (Rapid tests)

National Survey of IDUs Pilot test results IDU Never Ever Injection material sharing Never Ever First visit Never IDU Ever IDU n HIV+ p 25 325 128 177 47 38 (.%) 14 (4.3%) 3 (2.3%) 11 (6.2%) (.%) 2 (5.3%).1.165.197

HIV and Drug Users

The AIDS epidemic is not only about revealing injustice, but also about overcoming injustice. Peter Piot, February 27